Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Breckenridge Pharmaceutical has entered into a marketing and distribution agreement with Zhejiang Huahai Pharmaceuticals for Nevirapine tablets.
Subscribe to our email newsletter
Nevirapine 200mg tablets are AB rated to Viramune, which is marketed by Boehringer Ingelheim.
The non-nucleoside reverse transcriptase inhibitor (NNRTI) is indicated for the treatment of HIV-1 infection and AIDS.
Nevirapine tablets were awarded FDA tentative approval on 10 July 2007. Huahai has been distributing the product in Africa since then under the President’s Emergency Plan for Aids Relief plan.
The companies will launch the product in the US upon patent expiration, on 22 May 2012.